Biomarker testing in MCI patients-deciding who to test.

Ingrid S van MaurikHanneke F M Rhodius-MeesterCharlotte E TeunissenPhilip ScheltensFrederik BarkhofSebastian PalmqvistOskar HanssonWiesje M van der FlierJohannes Berkhof

Published in: Alzheimer's research & therapy (2021)

CSF biomarker testing adds prognostic value in half of the MCI patients. As such, we achieve a CSF saving recommendation while simultaneously retaining optimal prognostic accuracy.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
patient reported outcomes